Hikma Pharmaceuticals PLC
Open
SectorGezondheidszorg
1,474 -0.81
Overzicht
Wijziging aandelenprijs
24u
Min
1469
Max
1491
Inkomsten | 165M |
|---|---|
Verkoop | 41M 1.7B |
K/W Sectorgemiddelde | 10.771 49.052 |
EPS | 1.07 |
Dividendrendement | 5.74 |
Winstmarge | 9.698 |
Werknemers | 9,400 |
EBITDA | 152M 411M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +23.99% upside |
Dividendrendement Sectorgemiddelde | 5.74% 2.36% |
|---|---|
Volgende Winsten | 6 aug 2026 |
Volgende Ex Dividend datum | 13 aug 2026 |
Marktkapitalisatie | -526M 3.1B |
|---|---|
Vorige openingsprijs | 1474.81 |
Vorige sluitingsprijs | 1474 |
Nieuwssentiment
By Acuity
43%
57%
118 / 342 Rangschikking in Healthcare
Hikma Pharmaceuticals PLC Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.